> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Heron Submits PONV Drug NDA to FDA
- URL: https://www.fdaweb.com/heron-submits-ponv-drug-nda-to-fda/
- Published: 2021-11-18T12:00:00.000Z
- Updated: 2026-09-14T17:22:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150604

Heron Therapeutics says it has submitted an NDA for its HTX-019 (aprepitant) injectable emulsion indicated for preventing postoperative nausea and vomiting (PONV) in adults. A company [statement](https://www.marketwatch.com/press-release/heron-therapeutics-announces-submission-of-htx-019-nda-for-the-prevention-of-postoperative-nausea-and-vomiting-to-fda-2021-11-18?tesla=y&ref=fdaweb.com) says HTX-019 is a proprietary intravenous formulation of aprepitant that is approved for PONV prevention.

The injectable emulsion formulation intended for PONV prevention is identical to the approved Cinvanti (aprepitant) injectable emulsion formulation for preventing chemotherapy-induced nausea and vomiting, Heron says.

Aprepitant is the only P/neurokinin receptor antagonist to be approved for preventing PONV based on showing superiority to ondansetron (Zofran and others), the current standard of care, the company says.